0      0

2021 uroLogic Conference


164 - Immunotherapy in the Genitourinary Malignancies


Oct 29, 2021 4:45pm ‐ Oct 29, 2021 5:45pm

Description

Overview of recent treatment advances utilizing checkpoint inhibitor immunotherapy in urothelial carcinoma, renal cell carcinoma, and prostate cancer.

Continuing Education Instructions and Disclosure Information:

Contact hours available until 10/31/23.

Requirements for Successful Completion:

Complete the learning activity in its entirety and complete the online nursing continuing professional development evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.

Faculty, Planners, and Speakers Conflict of Interest Disclosure:

Planning Committee Disclosures:

There are no Planning Committee disclosures to declare.

Speakers Conflict of Interest Disclosure:
There are no speaker disclosures to declare.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

SUNA accreditation is reciprocal in the states and specialty organizations that recognize the ANCC-COA accreditation process. SUNA is also an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 5556. Accreditation and approved provider status of NCPD does not imply ANCC-COA approval or endorsement of any product, advertising, or educational content. SUNA urges all participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.

Learning Outcome:
After completing this education activity, the learner will be knowledgeable about the basic mechanism of action of checkpoint inhibitor immunotherapy to treat genitourinary malignancies.

Speaker(s):

You must be logged in and own this session in order to post comments.